WO2007110364A1 - Benzothiazoles presentant une activité sur le récepteur h3 de l'histamine - Google Patents
Benzothiazoles presentant une activité sur le récepteur h3 de l'histamine Download PDFInfo
- Publication number
- WO2007110364A1 WO2007110364A1 PCT/EP2007/052751 EP2007052751W WO2007110364A1 WO 2007110364 A1 WO2007110364 A1 WO 2007110364A1 EP 2007052751 W EP2007052751 W EP 2007052751W WO 2007110364 A1 WO2007110364 A1 WO 2007110364A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- piperazin
- mmol
- fumarate
- benzothiazole
- Prior art date
Links
- MJHJRHNCMCRNON-UHFFFAOYSA-N C(c(cc1)cc2c1[o]c(N(CC1)CCN1C1CC1)n2)N1CCCC1 Chemical compound C(c(cc1)cc2c1[o]c(N(CC1)CCN1C1CC1)n2)N1CCCC1 MJHJRHNCMCRNON-UHFFFAOYSA-N 0.000 description 1
- YXXTUOXZERUQLJ-UHFFFAOYSA-N C(c(cc1)cc2c1nc(N(CC1)CCN1C1CC1)[s]2)N1CCCCC1 Chemical compound C(c(cc1)cc2c1nc(N(CC1)CCN1C1CC1)[s]2)N1CCCCC1 YXXTUOXZERUQLJ-UHFFFAOYSA-N 0.000 description 1
- VJAJKYCGAJPQGQ-UHFFFAOYSA-N C(c(cc1)cc2c1nc(N(CC1)CCN1C1CC1)[s]2)N1CCOCC1 Chemical compound C(c(cc1)cc2c1nc(N(CC1)CCN1C1CC1)[s]2)N1CCOCC1 VJAJKYCGAJPQGQ-UHFFFAOYSA-N 0.000 description 1
- NYIMXMNHLGIGQF-UHFFFAOYSA-N NCc(cc1)cc2c1[o]c(N(CC1)CCN1C1CC1)n2 Chemical compound NCc(cc1)cc2c1[o]c(N(CC1)CCN1C1CC1)n2 NYIMXMNHLGIGQF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Abstract
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002645581A CA2645581A1 (fr) | 2006-03-28 | 2007-03-22 | Benzothiazoles presentant une activite sur le recepteur h3 de l'histamine |
CN2007800109712A CN101410385B (zh) | 2006-03-28 | 2007-03-22 | 具有组胺h3受体活性的苯并噻唑类 |
AU2007229492A AU2007229492B2 (en) | 2006-03-28 | 2007-03-22 | Benzothiazoles having histamine H3 receptor activity |
EP07727226A EP1999120B1 (fr) | 2006-03-28 | 2007-03-22 | Benzothiazoles présentant une activité sur le récepteur h3 de l'histamine |
BRPI0709187-7A BRPI0709187A2 (pt) | 2006-03-28 | 2007-03-22 | benzotiazóis tendo atividade no receptor h3 de histamina |
JP2009502034A JP2009531376A (ja) | 2006-03-28 | 2007-03-22 | ヒスタミンh3受容体活性を有するベンゾチアゾール |
KR1020087023919A KR101280333B1 (ko) | 2006-03-28 | 2007-03-22 | 히스타민 h3 수용체 활성을 갖는 벤조티아졸 |
MX2008011123A MX2008011123A (es) | 2006-03-28 | 2007-03-22 | Benzotiazoles que tienen actividad de receptor h3 de histamina. |
ES07727226T ES2388681T3 (es) | 2006-03-28 | 2007-03-22 | Benzotiazoles con actividad de los receptores de histamina H3 |
NZ570524A NZ570524A (en) | 2006-03-28 | 2007-03-22 | Benzothiazoles having histamine H3 receptor activity |
EA200870376A EA015569B1 (ru) | 2006-03-28 | 2007-03-22 | Бензотиазолы, обладающие антагонистической активностью по отношению к h3-рецептору гистамина, и фармацевтические композиции, включающие эти соединения |
US12/294,756 US8394842B2 (en) | 2006-03-28 | 2007-03-22 | Benzothiazoles having histamine H3 receptor activity |
ZA2008/06985A ZA200806985B (en) | 2006-03-28 | 2008-08-13 | Benzothiazole having histamine h3 receptor activity |
IL193441A IL193441A0 (en) | 2006-03-28 | 2008-08-14 | Benzothiazoles having histamine h3 receptor activity |
HK09107300.1A HK1129102A1 (en) | 2006-03-28 | 2009-08-10 | Benzothiazoles having histamine h3 receptor activity |
US13/660,045 US8772285B2 (en) | 2006-03-28 | 2012-10-25 | Benzothiazoles having histamine H3 receptor activity |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06111820.4 | 2006-03-28 | ||
EP06111820 | 2006-03-28 | ||
US78747806P | 2006-03-30 | 2006-03-30 | |
US60/787,478 | 2006-03-30 | ||
EP06112425 | 2006-04-10 | ||
EP06112425.1 | 2006-04-10 | ||
US79428806P | 2006-04-21 | 2006-04-21 | |
US60/794,288 | 2006-04-21 | ||
EP06026875 | 2006-12-24 | ||
EP06026875.2 | 2006-12-24 | ||
US90350307P | 2007-02-26 | 2007-02-26 | |
US60/903,503 | 2007-02-26 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US29475608A Substitution | 2006-03-28 | 2008-09-26 | |
US13/660,045 Division US8772285B2 (en) | 2006-03-28 | 2012-10-25 | Benzothiazoles having histamine H3 receptor activity |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007110364A1 true WO2007110364A1 (fr) | 2007-10-04 |
Family
ID=43124961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/052751 WO2007110364A1 (fr) | 2006-03-28 | 2007-03-22 | Benzothiazoles presentant une activité sur le récepteur h3 de l'histamine |
Country Status (16)
Country | Link |
---|---|
US (2) | US8394842B2 (fr) |
EP (1) | EP1999120B1 (fr) |
JP (1) | JP2009531376A (fr) |
KR (1) | KR101280333B1 (fr) |
CN (1) | CN101410385B (fr) |
AU (1) | AU2007229492B2 (fr) |
CA (1) | CA2645581A1 (fr) |
EA (1) | EA015569B1 (fr) |
ES (1) | ES2388681T3 (fr) |
HK (1) | HK1129102A1 (fr) |
IL (1) | IL193441A0 (fr) |
MX (1) | MX2008011123A (fr) |
NZ (1) | NZ570524A (fr) |
SG (1) | SG170785A1 (fr) |
WO (1) | WO2007110364A1 (fr) |
ZA (1) | ZA200806985B (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009021740A2 (fr) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments |
WO2010109084A3 (fr) * | 2009-03-24 | 2011-01-06 | Sanofi-Aventis | DERIVES D'AZACARBOLINES 9H-PYRROLO[2,3-b:5,4-c']DIPYRIDINE, LEUR PREPARATION ET LEUR UTILISATION THERAPEUTIQUE |
JP2011507884A (ja) * | 2007-12-20 | 2011-03-10 | アボット・ラボラトリーズ | ベンゾチアゾールおよびベンゾオキサゾール誘導体ならびに使用方法 |
WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
WO2012120055A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120056A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
JP2013514990A (ja) * | 2009-12-18 | 2013-05-02 | ヤンセン ファーマシューティカ エヌ.ベー. | Dpp−1の阻害剤として有用な置換ベンゾチアゾール誘導体及び置換ベンゾオキサゾール誘導体 |
WO2016207785A1 (fr) | 2015-06-22 | 2016-12-29 | Actelion Pharmaceuticals Ltd | Inhibiteurs de la nadph oxydase 4 |
WO2017153601A1 (fr) * | 2016-03-11 | 2017-09-14 | Ac Immune Sa | Composés bicycliques pour diagnostic et traitement |
US9777018B2 (en) | 2011-06-09 | 2017-10-03 | Rhizen Pharmaceuticals Sa | Compounds as modulators of GPR-119 |
US20210284660A1 (en) * | 2018-06-27 | 2021-09-16 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
US11780839B2 (en) | 2018-03-27 | 2023-10-10 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
US11858941B2 (en) | 2018-06-27 | 2024-01-02 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030236259A1 (en) * | 2002-02-05 | 2003-12-25 | Rolf Hohlweg | Novel aryl- and heteroarylpiperazines |
ES2375929T3 (es) | 2005-07-04 | 2012-03-07 | High Point Pharmaceuticals, Llc | Antagonistas del receptor histamina h3. |
CA2653062A1 (fr) * | 2006-05-23 | 2007-11-29 | Transtech Pharma, Inc. | Nouveaux medicaments |
PT2079732E (pt) * | 2006-05-29 | 2012-02-02 | High Point Pharmaceuticals Llc | 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)- piridazina, os seus sais e solvatos e a sua utilização a título de antagonista do receptor h3 de histamina |
EP2014656A3 (fr) * | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | Nouveaux antagonistes d'hétéocycliques h3 |
WO2012029070A1 (fr) * | 2010-09-02 | 2012-03-08 | Suven Life Sciences Limited | Composés hétérocyclyle comme ligands des récepteurs h3 de l'histamine |
TWI650321B (zh) * | 2011-10-14 | 2019-02-11 | 美商安比特生物科學公司 | 雜環化合物及其使用方法 |
MX2015016965A (es) * | 2013-06-10 | 2016-04-25 | Astellas Pharma Inc | Compuesto de amida heterociclica aromatica que contiene nitrogeno biciclico. |
CN106588808A (zh) * | 2017-02-26 | 2017-04-26 | 长沙深橙生物科技有限公司 | 一种苯并[d]恶唑衍生物的制备方法 |
KR20220153888A (ko) * | 2021-05-12 | 2022-11-21 | 에이치케이이노엔 주식회사 | 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도 |
Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2825407A1 (de) * | 1977-06-10 | 1978-12-14 | Science Union & Cie | Piperazindithiocarbonsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
EP0214826A2 (fr) | 1985-08-30 | 1987-03-18 | Novo Nordisk A/S | Analogues d'insuline et leur méthode de préparation |
EP0368187A2 (fr) | 1988-11-08 | 1990-05-16 | Hoechst Aktiengesellschaft | Dérivés d'insuline, leur emploi et une composition pharmaceutique les contenant |
JPH02306916A (ja) * | 1989-05-22 | 1990-12-20 | Otsuka Pharmaceut Co Ltd | 血小板粘着抑制剤 |
US5504188A (en) | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
EP0705275A1 (fr) | 1993-06-21 | 1996-04-10 | Novo Nordisk A/S | Cristaux d'insuline asp?b28 |
WO1997026265A1 (fr) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Derives de 1,2,4-thiadiazine fusionnee et de 1,4-thiazine fusionnee, leur preparation et utilisation |
EP0792290A1 (fr) | 1993-09-17 | 1997-09-03 | Novo Nordisk A/S | Insuline acylee |
WO1997041120A1 (fr) | 1996-07-26 | 1997-11-06 | Dr. Reddy's Research Foundation | Composes de thiazolidinedione presentant des proprietes antidiabetiques, hypolipidemiantes, antihypertensives, leur procede de preparation et compositions pharmaceutiques les contenant |
WO1997041119A1 (fr) | 1997-05-02 | 1997-11-06 | Dr. Reddy's Research Foundation | Nouveaux composes anti-diabetiques avec proprietes hypolipidemiantes et anti-hypertensives, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
WO1997041097A2 (fr) | 1996-12-31 | 1997-11-06 | Dr. Reddy's Research Foundation | Nouveaux composes heterocycliques, leur procede de preparation, compositions pharmaceutiques les contenant et utilisation de ces composes dans le traitement du diabete et des maladies associees |
WO1998008871A1 (fr) | 1996-08-30 | 1998-03-05 | Novo Nordisk A/S | Derives de glp-1 |
WO1998045292A1 (fr) | 1997-12-02 | 1998-10-15 | Dr. Reddy's Research Foundation | Derives de thiazolidinedione et d'oxazolidinedione ayant des proprietes antidiabetiques, hypolipidemiques et antihypertenseurs |
WO1999001423A1 (fr) | 1997-07-01 | 1999-01-14 | Novo Nordisk A/S | Antagonistes/agonistes inverses du glucagon |
WO1999003861A1 (fr) | 1997-07-16 | 1999-01-28 | Novo Nordisk A/S | Derives de 1,2,4-thiadiazine fusionnee, leur preparation et utilisation |
WO1999019313A1 (fr) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant |
JPH11199573A (ja) * | 1998-01-07 | 1999-07-27 | Yamanouchi Pharmaceut Co Ltd | 5ht3受容体作動薬及び新規ベンゾチアゾール誘導体 |
WO2000023415A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, preparation et utilisation correspondantes |
WO2000023451A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
WO2000023445A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
WO2000023417A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
WO2000023425A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, preparation et utilisation correspondantes |
WO2000023416A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
WO2000037474A1 (fr) | 1998-12-18 | 2000-06-29 | Novo Nordisk A/S | Derives de 1,2,4-thiadiazine fusionnes, leur preparation et utilisation |
WO2000039088A1 (fr) | 1998-12-23 | 2000-07-06 | Novo Nordisk A/S | Antagonistes de glucagon/agonistes inverses |
WO2000041121A1 (fr) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Procede et dispositif d'emission et de gestion de bons numeriques et d'offres de vente |
WO2000042026A1 (fr) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Agonistes non peptidiques de glp-1 |
WO2000050414A1 (fr) | 1999-02-24 | 2000-08-31 | Dr.Reddy's Research Foundation | Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ceux-ci et composition pharmaceutique les contenant |
US6130217A (en) * | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
WO2000063189A1 (fr) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Formes cristallines de r-guanidines, d'arginine ou de (l)-arginine (2s-2-ethoxy-3-{4-[2-(10h-phenoxazin-10-yl)ethoxy]phenyl}propanoate |
WO2000063196A1 (fr) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
WO2000063192A1 (fr) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant |
WO2000063209A1 (fr) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | Nouveaux composes, preparation et utilisation associees |
WO2000063153A1 (fr) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | Nouveaux composes, preparation et utilisation de ces derniers |
WO2000063190A1 (fr) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | Nouveaux composes, leur preparation et utilisation |
WO2000063191A1 (fr) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Nouvelles formes polymorphes d'un agent antidiabetique: procede de preparation et composition pharmaceutique contenant ces dernieres |
EP1134220A1 (fr) | 1998-11-20 | 2001-09-19 | Meiji Seika Kaisha Ltd. | Derives de benzoxazole et produits a base de ces derniers utilises comme ingredient actif |
WO2002014271A1 (fr) * | 2000-08-10 | 2002-02-21 | Mitsubishi Pharma Corporation | Dérivés de proline et leur utilisation comme médicaments |
US20030073672A1 (en) * | 2001-09-05 | 2003-04-17 | Breitenbucher J. Guy | Method for treating allergies using substituted pyrazoles |
WO2003066604A2 (fr) * | 2002-02-05 | 2003-08-14 | Novo Nordisk A/S | Nouvelles aryl- et heteroarylpiperazines |
WO2004101559A1 (fr) * | 2003-05-07 | 2004-11-25 | Abbott Laboratories | Amines substituees bicycliques hybrides servant de ligands au recepteur d'histamine 3 |
US20050059663A1 (en) * | 2003-03-12 | 2005-03-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO156497C (no) | 1984-10-18 | 1987-09-30 | Helge Boe | Anordning for sammenfoeyning av to plateformede elementer. |
DE3511110A1 (de) | 1985-03-27 | 1986-10-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue pyridazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel |
FI91859C (fi) | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
JP2637303B2 (ja) | 1991-04-16 | 1997-08-06 | 明治製菓株式会社 | 新規ベンゾチアゾール誘導体 |
DE4223589A1 (de) | 1992-07-17 | 1994-01-20 | Fluehs Drehtechnik Gmbh | Ventiloberteil |
WO1994022846A1 (fr) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Composes stimulant l'activite antitumorale d'autres agents cytotoxiques |
JP3193560B2 (ja) | 1993-04-16 | 2001-07-30 | 明治製菓株式会社 | 新規ベンゾオキサゾール誘導体 |
JP3520177B2 (ja) | 1996-05-09 | 2004-04-19 | 明治製菓株式会社 | セロトニン5−ht3受容体部分活性薬 |
CN1239570A (zh) | 1997-07-17 | 1999-12-22 | 索尼公司 | 磁记录介质和使用该介质的磁记录/再现装置 |
ES2267873T3 (es) | 1997-10-27 | 2007-03-16 | Agouron Pharmaceuticals, Inc. | Derivados de 4-aminotiazol, su preparacion y uso como inhibidores de kinasas dependientes de ciclina. |
AU1045300A (en) | 1998-11-17 | 2000-06-05 | Bayer Aktiengesellschaft | Novel heterocyclyl-substituted oxazolidone derivatives |
GB0003254D0 (en) | 2000-02-11 | 2000-04-05 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
US6436939B2 (en) | 2000-03-31 | 2002-08-20 | Ortho-Mcneil Pharmaceutical, Inc. | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists |
DE60138605D1 (de) | 2000-03-31 | 2009-06-18 | Ortho Mcneil Pharm Inc | Phenyl-substituierte indole als h3 histaminrezeptorantagonisten |
US7576084B2 (en) | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
CN101312968A (zh) | 2005-09-23 | 2008-11-26 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途 |
-
2007
- 2007-03-22 CA CA002645581A patent/CA2645581A1/fr not_active Abandoned
- 2007-03-22 CN CN2007800109712A patent/CN101410385B/zh not_active Expired - Fee Related
- 2007-03-22 JP JP2009502034A patent/JP2009531376A/ja active Pending
- 2007-03-22 MX MX2008011123A patent/MX2008011123A/es active IP Right Grant
- 2007-03-22 KR KR1020087023919A patent/KR101280333B1/ko not_active IP Right Cessation
- 2007-03-22 EA EA200870376A patent/EA015569B1/ru not_active IP Right Cessation
- 2007-03-22 NZ NZ570524A patent/NZ570524A/en not_active IP Right Cessation
- 2007-03-22 US US12/294,756 patent/US8394842B2/en not_active Expired - Fee Related
- 2007-03-22 EP EP07727226A patent/EP1999120B1/fr active Active
- 2007-03-22 ES ES07727226T patent/ES2388681T3/es active Active
- 2007-03-22 SG SG201102188-8A patent/SG170785A1/en unknown
- 2007-03-22 AU AU2007229492A patent/AU2007229492B2/en not_active Ceased
- 2007-03-22 WO PCT/EP2007/052751 patent/WO2007110364A1/fr active Application Filing
-
2008
- 2008-08-13 ZA ZA2008/06985A patent/ZA200806985B/en unknown
- 2008-08-14 IL IL193441A patent/IL193441A0/en unknown
-
2009
- 2009-08-10 HK HK09107300.1A patent/HK1129102A1/xx not_active IP Right Cessation
-
2012
- 2012-10-25 US US13/660,045 patent/US8772285B2/en not_active Expired - Fee Related
Patent Citations (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2825407A1 (de) * | 1977-06-10 | 1978-12-14 | Science Union & Cie | Piperazindithiocarbonsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
EP0214826A2 (fr) | 1985-08-30 | 1987-03-18 | Novo Nordisk A/S | Analogues d'insuline et leur méthode de préparation |
EP0368187A2 (fr) | 1988-11-08 | 1990-05-16 | Hoechst Aktiengesellschaft | Dérivés d'insuline, leur emploi et une composition pharmaceutique les contenant |
JPH02306916A (ja) * | 1989-05-22 | 1990-12-20 | Otsuka Pharmaceut Co Ltd | 血小板粘着抑制剤 |
EP0705275A1 (fr) | 1993-06-21 | 1996-04-10 | Novo Nordisk A/S | Cristaux d'insuline asp?b28 |
EP0792290A1 (fr) | 1993-09-17 | 1997-09-03 | Novo Nordisk A/S | Insuline acylee |
US5504188A (en) | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
US6130217A (en) * | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
WO1997026265A1 (fr) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Derives de 1,2,4-thiadiazine fusionnee et de 1,4-thiazine fusionnee, leur preparation et utilisation |
WO1997041120A1 (fr) | 1996-07-26 | 1997-11-06 | Dr. Reddy's Research Foundation | Composes de thiazolidinedione presentant des proprietes antidiabetiques, hypolipidemiantes, antihypertensives, leur procede de preparation et compositions pharmaceutiques les contenant |
WO1998008871A1 (fr) | 1996-08-30 | 1998-03-05 | Novo Nordisk A/S | Derives de glp-1 |
WO1997041097A2 (fr) | 1996-12-31 | 1997-11-06 | Dr. Reddy's Research Foundation | Nouveaux composes heterocycliques, leur procede de preparation, compositions pharmaceutiques les contenant et utilisation de ces composes dans le traitement du diabete et des maladies associees |
WO1997041119A1 (fr) | 1997-05-02 | 1997-11-06 | Dr. Reddy's Research Foundation | Nouveaux composes anti-diabetiques avec proprietes hypolipidemiantes et anti-hypertensives, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
WO1999001423A1 (fr) | 1997-07-01 | 1999-01-14 | Novo Nordisk A/S | Antagonistes/agonistes inverses du glucagon |
WO1999003861A1 (fr) | 1997-07-16 | 1999-01-28 | Novo Nordisk A/S | Derives de 1,2,4-thiadiazine fusionnee, leur preparation et utilisation |
WO1999019313A1 (fr) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant |
WO1998045292A1 (fr) | 1997-12-02 | 1998-10-15 | Dr. Reddy's Research Foundation | Derives de thiazolidinedione et d'oxazolidinedione ayant des proprietes antidiabetiques, hypolipidemiques et antihypertenseurs |
JPH11199573A (ja) * | 1998-01-07 | 1999-07-27 | Yamanouchi Pharmaceut Co Ltd | 5ht3受容体作動薬及び新規ベンゾチアゾール誘導体 |
WO2000023417A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
WO2000023415A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, preparation et utilisation correspondantes |
WO2000023451A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
WO2000023425A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, preparation et utilisation correspondantes |
WO2000023416A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
WO2000023445A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
EP1134220A1 (fr) | 1998-11-20 | 2001-09-19 | Meiji Seika Kaisha Ltd. | Derives de benzoxazole et produits a base de ces derniers utilises comme ingredient actif |
WO2000037474A1 (fr) | 1998-12-18 | 2000-06-29 | Novo Nordisk A/S | Derives de 1,2,4-thiadiazine fusionnes, leur preparation et utilisation |
WO2000039088A1 (fr) | 1998-12-23 | 2000-07-06 | Novo Nordisk A/S | Antagonistes de glucagon/agonistes inverses |
WO2000041121A1 (fr) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Procede et dispositif d'emission et de gestion de bons numeriques et d'offres de vente |
WO2000042026A1 (fr) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Agonistes non peptidiques de glp-1 |
WO2000050414A1 (fr) | 1999-02-24 | 2000-08-31 | Dr.Reddy's Research Foundation | Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ceux-ci et composition pharmaceutique les contenant |
WO2000063192A1 (fr) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant |
WO2000063193A1 (fr) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Nouvelles formes polymorphes d'un agent antidiabetique: leur procede de preparation et composition pharmaceutique contenant lesdites formes |
WO2000063191A1 (fr) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Nouvelles formes polymorphes d'un agent antidiabetique: procede de preparation et composition pharmaceutique contenant ces dernieres |
WO2000063189A1 (fr) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Formes cristallines de r-guanidines, d'arginine ou de (l)-arginine (2s-2-ethoxy-3-{4-[2-(10h-phenoxazin-10-yl)ethoxy]phenyl}propanoate |
WO2000063196A1 (fr) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
WO2000063209A1 (fr) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | Nouveaux composes, preparation et utilisation associees |
WO2000063153A1 (fr) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | Nouveaux composes, preparation et utilisation de ces derniers |
WO2000063190A1 (fr) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | Nouveaux composes, leur preparation et utilisation |
WO2002014271A1 (fr) * | 2000-08-10 | 2002-02-21 | Mitsubishi Pharma Corporation | Dérivés de proline et leur utilisation comme médicaments |
US20030073672A1 (en) * | 2001-09-05 | 2003-04-17 | Breitenbucher J. Guy | Method for treating allergies using substituted pyrazoles |
WO2003066604A2 (fr) * | 2002-02-05 | 2003-08-14 | Novo Nordisk A/S | Nouvelles aryl- et heteroarylpiperazines |
US20050059663A1 (en) * | 2003-03-12 | 2005-03-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
WO2004101559A1 (fr) * | 2003-05-07 | 2004-11-25 | Abbott Laboratories | Amines substituees bicycliques hybrides servant de ligands au recepteur d'histamine 3 |
Non-Patent Citations (23)
Title |
---|
"Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING CO. |
ARCH PHARM PHARM MED |
ARCH PHARM PHARM MED CHEM, vol. 332, 1999, pages 389 - 98 |
CELANIRE ET AL: "Keynote review: Histamine H3 receptor antagonists reach out for the clinic", DDT - DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, GB, vol. 10, no. 23-24, December 2005 (2005-12-01), pages 1613 - 1627, XP005222014, ISSN: 1359-6446 * |
CHEM. PHARM. BULL., vol. 46, 1998, pages 445 - 451 |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IWAOKA, KIYOSHI ET AL: "Benzothiazoles and 5-HT3 receptor agonists containing them", XP002396638, retrieved from STN Database accession no. 1999:463258 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KITAJIMA, HIROSHI ET AL: "Preparation of proline derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors and use thereof as drugs", XP002396637, retrieved from STN Database accession no. 2002:142666 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NISHI, TAKAO ET AL: "Preparation of benzothiazoles and benzimidazoles as blood platelet aggregation inhibitors", XP002396639, retrieved from STN Database accession no. 1991:207259 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SATO, YASUO ET AL: "Preparation of benzothiazoles as cardiotonics", XP002396640, retrieved from STN Database accession no. 1993:161060 * |
DRUGS FUT, vol. 21, 1996, pages 507 - 20 |
EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 9, 2000, pages 2537 - 42 |
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 10, 2000, pages 1045 - 55 |
J MED CHEM, vol. 43, 2000, pages 2362 - 70 |
J PHARM SCI, vol. 66, 1977, pages 2 |
J. MED. CHEM, vol. 41, 1998, pages 3015 - 3021 |
J. MED. CHEM, vol. 48, 2005, pages 7075 - 7079 |
MOLECULAR PHARMACOLOGY, vol. 55, 1999, pages 1101 - 7 |
NATURE, vol. 408, 2000, pages 860 - 4 |
PROGRESS IN DRUG RESEARCH, vol. 45, 1995, pages 107 - 65 |
SATO Y ET AL: "Benzoxazole Derivatives as Novel 5-HT3 Receptor Partial Agonists in the Gut", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 16, 1998, pages 3015 - 3021, XP002180160, ISSN: 0022-2623 * |
THE JOURNAL OF PHANTIACOLOGYAND EXPERIMENTAL THERAPEUTICS, vol. 287, 1998, pages 43 - 50 |
YAMADA M ET AL: "A new 5-HT3 receptor ligand. II. Structure-activity analysis of 5-HT3 receptor agonist action in the gut", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 46, no. 3, 1998, pages 445 - 451, XP002403658, ISSN: 0009-2363 * |
YOSHIDA, SATOSHI ET AL: "Orally Active Benzoxazole Derivative as 5-HT3 Receptor Partial Agonist for Treatment of Diarrhea-Predominant Irritable Bowel Syndrome", JOURNAL OF MEDICINAL CHEMISTRY , 48(22), 7075-7079 CODEN: JMCMAR; ISSN: 0022-2623, 2005, XP002437776 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009021740A2 (fr) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Nouvelles tétrahydronaphtalines substituées, leurs procédés de préparation et leur utilisation comme médicaments |
JP2011507884A (ja) * | 2007-12-20 | 2011-03-10 | アボット・ラボラトリーズ | ベンゾチアゾールおよびベンゾオキサゾール誘導体ならびに使用方法 |
WO2010109084A3 (fr) * | 2009-03-24 | 2011-01-06 | Sanofi-Aventis | DERIVES D'AZACARBOLINES 9H-PYRROLO[2,3-b:5,4-c']DIPYRIDINE, LEUR PREPARATION ET LEUR UTILISATION THERAPEUTIQUE |
CN102365282A (zh) * | 2009-03-24 | 2012-02-29 | 赛诺菲 | 9H-吡咯并[2,3-b:5,4-c’]二吡啶氮杂咔啉衍生物、其制备方法及其治疗用途 |
JP2013514990A (ja) * | 2009-12-18 | 2013-05-02 | ヤンセン ファーマシューティカ エヌ.ベー. | Dpp−1の阻害剤として有用な置換ベンゾチアゾール誘導体及び置換ベンゾオキサゾール誘導体 |
WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
WO2012120055A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120056A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
US9777018B2 (en) | 2011-06-09 | 2017-10-03 | Rhizen Pharmaceuticals Sa | Compounds as modulators of GPR-119 |
WO2016207785A1 (fr) | 2015-06-22 | 2016-12-29 | Actelion Pharmaceuticals Ltd | Inhibiteurs de la nadph oxydase 4 |
US10584118B2 (en) | 2015-06-22 | 2020-03-10 | Actelion Pharmaceuticals Ltd | NADPH oxidase 4 inhibitors |
US11136317B2 (en) | 2015-06-22 | 2021-10-05 | Actelion Pharmaceuticals Ltd | NADPH oxidase 4 inhibitors |
WO2017153601A1 (fr) * | 2016-03-11 | 2017-09-14 | Ac Immune Sa | Composés bicycliques pour diagnostic et traitement |
EP4001277A3 (fr) * | 2016-03-11 | 2022-09-14 | AC Immune SA | Composes bicycliques pour le diagnostic et le traitement |
KR20220151042A (ko) * | 2016-03-11 | 2022-11-11 | 에이씨 이뮨 에스에이 | 진단 및 치료를 위한 바이사이클릭 화합물 |
KR102646115B1 (ko) * | 2016-03-11 | 2024-03-12 | 에이씨 이뮨 에스에이 | 진단 및 치료를 위한 바이사이클릭 화합물 |
US11780839B2 (en) | 2018-03-27 | 2023-10-10 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
US20210284660A1 (en) * | 2018-06-27 | 2021-09-16 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
US11858941B2 (en) | 2018-06-27 | 2024-01-02 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
Also Published As
Publication number | Publication date |
---|---|
MX2008011123A (es) | 2008-09-30 |
US20100298316A1 (en) | 2010-11-25 |
US8772285B2 (en) | 2014-07-08 |
KR20080104042A (ko) | 2008-11-28 |
CA2645581A1 (fr) | 2007-10-04 |
AU2007229492A1 (en) | 2007-10-04 |
US20130079340A1 (en) | 2013-03-28 |
SG170785A1 (en) | 2011-05-30 |
EP1999120B1 (fr) | 2012-06-27 |
AU2007229492B2 (en) | 2011-11-03 |
KR101280333B1 (ko) | 2013-07-02 |
JP2009531376A (ja) | 2009-09-03 |
US8394842B2 (en) | 2013-03-12 |
EP1999120A1 (fr) | 2008-12-10 |
CN101410385A (zh) | 2009-04-15 |
CN101410385B (zh) | 2011-08-24 |
NZ570524A (en) | 2011-08-26 |
EA015569B1 (ru) | 2011-10-31 |
ZA200806985B (en) | 2010-12-29 |
HK1129102A1 (en) | 2009-11-20 |
ES2388681T3 (es) | 2012-10-17 |
IL193441A0 (en) | 2009-05-04 |
EA200870376A1 (ru) | 2009-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8772285B2 (en) | Benzothiazoles having histamine H3 receptor activity | |
US8344001B2 (en) | Heterocyclic H3 antagonists | |
US8501739B2 (en) | Medicaments | |
JP5492092B2 (ja) | Cb2受容体を調節する化合物 | |
JP2011500820A (ja) | Cb2受容体を制御するジアゼパン化合物 | |
EP2019823A2 (fr) | Activateurs de la glucokinase benzamidique | |
EP1585515A2 (fr) | Derives d'homopiperdine, de piperidine ou de pyrrolidine substitues | |
US20120184544A1 (en) | Substituted benzamide derivatives as glucokinase (gk) activators | |
BRPI0709187A2 (pt) | benzotiazóis tendo atividade no receptor h3 de histamina | |
AU2012244121A1 (en) | Histamine H3 receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07727226 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 570524 Country of ref document: NZ Ref document number: 193441 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007229492 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7286/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/011123 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2007229492 Country of ref document: AU Date of ref document: 20070322 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2645581 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780010971.2 Country of ref document: CN Ref document number: 2009502034 Country of ref document: JP Ref document number: 12294756 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087023919 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007727226 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200870376 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: PI0709187 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080926 |